Vivesto AB ADR (OASMY)
OTHER OTC:OASMY
OASMY Stock Chart & Stats
$0.01
-$0.01(-20.00%)
At close: 4:00 PM EST
$0.01
-$0.01(-20.00%)
Day’s Range― - ―
52-Week Range$0.02 - $0.02
Previous CloseN/A
Volume4.30K
Average Volume (3M)105.00
Market Cap
$9.18M
Enterprise Value$52.09M
Total Cash (Recent Filing)$2.10M
Total Debt (Recent Filing)$13.00M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding369,045,620
10 Day Avg. Volume15
30 Day Avg. Volume105
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.03
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap5.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-65.36
Enterprise Value/Ebitda-2.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA low debt-to-equity (~0.10) reduces fixed financing obligations and interest exposure, giving the company more financial flexibility to fund R&D or survive setbacks without immediate refinancing. This durability lowers bankruptcy risk during extended clinical timelines.
Improving Cash BurnA reduction in cash burn signals better cost control or milestone-driven inflows, extending runway and increasing the odds of reaching pivotal development or partnering milestones without urgent capital raises. That trend supports near-term operational continuity.
Asset-monetization Business ModelA licensing/out‑licensing and milestone/royalty revenue model is capital-efficient for a small oncology firm: it allows value realization without full commercialization buildout, enables risk-sharing with partners, and can produce non-linear cash inflections at key milestones.
Bears Say
Persistent UnprofitabilityContinued negative EBIT and operating cash flow erode shareholder capital, limit the firm's ability to self-fund trials or launches, and increase reliance on external financing. Over time this raises dilution and execution risk for a small biotech with long development cycles.
Revenue CollapsedEffectively zero recent revenue removes operating leverage and commercial validation, making future cash generation highly uncertain. This lack of recurring income heightens dependency on partner deals or capital markets, weakening negotiating leverage and predictability.
Eroding Balance SheetMaterial declines in assets and equity indicate the balance sheet has been consumed by losses, reducing collateral and borrowing capacity. That erosion increases solvency and runway risk, raising the probability of dilutive financings or constrained strategic options.
Vivesto AB ADR News
OASMY FAQ
What was Vivesto AB ADR’s price range in the past 12 months?
Vivesto AB ADR lowest stock price was $0.02 and its highest was $0.02 in the past 12 months.
What is Vivesto AB ADR’s market cap?
Vivesto AB ADR’s market cap is $9.18M.
When is Vivesto AB ADR’s upcoming earnings report date?
Vivesto AB ADR’s upcoming earnings report date is May 21, 2026 which is in 37 days.
How were Vivesto AB ADR’s earnings last quarter?
Vivesto AB ADR released its earnings results on Feb 12, 2026. The company reported -$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.005.
Is Vivesto AB ADR overvalued?
According to Wall Street analysts Vivesto AB ADR’s price is currently Overvalued.
Does Vivesto AB ADR pay dividends?
Vivesto AB ADR pays a Notavailable dividend of $0.003 which represents an annual dividend yield of N/A. See more information on Vivesto AB ADR dividends here
What is Vivesto AB ADR’s EPS estimate?
Vivesto AB ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivesto AB ADR have?
Vivesto AB ADR has 369,045,620 shares outstanding.
What happened to Vivesto AB ADR’s price movement after its last earnings report?
Vivesto AB ADR reported an EPS of -$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vivesto AB ADR?
Currently, no hedge funds are holding shares in OASMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivesto AB ADR
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---